Molecular guided therapy for advanced pancreatic cancer patients with PI3K activated mutation: vision or illusion?
Received 25 September 2012
Accepted for publication 25 October 2012
Published 20 February 2013 Volume 2013:6 Pages 95—97
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Anas Gazzah,1 Daniel Barrios Gonzales,1 Antonin Levy,1 Rastislav Bahleda,1 Michel Ducreux,2 Ludovic Lacroix,3 Jean Charles Soria1
1SITEP (Service des Innovations Therapeutiques Précoces), Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France; 2Department of Medicine, Institut Gustave Roussy, Paris XI University, Villejuif, France; 3Department of Biology, Institut Gustave Roussy, Paris XI University, Villejuif, France
Abstract: Despite a modern validated regimen of chemotherapy, advanced pancreatic adenocarcinoma remains the fourth most common cause of cancer-related death worldwide. The phosphoinositide 3-kinase pathway (PI3K)/Akt/mammalian target of rapamycin (mTOR) is a major signaling pathway that may be activated in advanced pancreatic cancer. To highlight the potential interest of this targetable pathway in selected advanced pancreatic cancer patients, we report herein a patient with an activated PI3K mutation who was treated in a phase I trial evaluating a treatment combination including an mTOR inhibitor.
Keywords: pancreatic cancer, PI3K, targeted therapy, molecular profiling
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]